These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8245876)

  • 21. Failure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants.
    Bailey TC; Ettinger NA; Storch GA; Trulock EP; Hanto DW; Dunagan WC; Jendrisak MD; McCullough CS; Kenzora JL; Powderly WG
    Am J Med; 1993 Sep; 95(3):273-8. PubMed ID: 8396320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful prophylaxis of cytomegalovirus disease after primary CMV exposure in liver transplant recipients.
    Stratta RJ; Shaefer MS; Cushing KA; Markin RS; Wood RP; Langnas AN; Reed EC; Woods GL; Donovan JP; Pillen TJ
    Transplantation; 1991 Jan; 51(1):90-7. PubMed ID: 1846254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group.
    Prentice HG; Gluckman E; Powles RL; Ljungman P; Milpied N; Fernandez Rañada JM; Mandelli F; Kho P; Kennedy L; Bell AR
    Lancet; 1994 Mar; 343(8900):749-53. PubMed ID: 7907729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Failure of acyclovir to prevent cytomegalovirus infection in renal allograft recipients.
    Wong T; Lavaud S; Toupance O; Carquin J; Wynckel A; Melin JP; Hanrotel C; Chanard J
    Transpl Int; 1993; 6(5):285-9. PubMed ID: 8216706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
    BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3.
    Hibberd PL; Tolkoff-Rubin NE; Cosimi AB; Schooley RT; Isaacson D; Doran M; Delvecchio A; Delmonico FL; Auchincloss H; Rubin RH
    Transplantation; 1992 Jan; 53(1):68-72. PubMed ID: 1310173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
    Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
    Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients.
    Dickinson BI; Gora-Harper ML; McCraney SA; Gosland M
    Ann Pharmacother; 1996 Dec; 30(12):1452-64. PubMed ID: 8968459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation.
    Dunn DL; Gillingham KJ; Kramer MA; Schmidt WJ; Erice A; Balfour HH; Gores PF; Gruessner RW; Matas AJ; Payne WD
    Transplantation; 1994 Mar; 57(6):876-84. PubMed ID: 8154035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group.
    Prentice HG; Gluckman E; Powles RL; Ljungman P; Milpied NJ; Camara R; Mandelli F; Kho P; Kennedy L; Bell AR
    Bone Marrow Transplant; 1997 Jan; 19(2):129-33. PubMed ID: 9116609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of ganciclovir- and immune globulin-containing regimens in preventing cytomegalovirus infection in patients with renal transplants.
    Walton T; Sankari B; Wyner L
    Am J Health Syst Pharm; 1999 Sep; 56(18):1831-4. PubMed ID: 10511232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.
    Pavlopoulou ID; Syriopoulou VP; Chelioti H; Daikos GL; Stamatiades D; Kostakis A; Boletis JN
    Clin Microbiol Infect; 2005 Sep; 11(9):736-43. PubMed ID: 16104989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytomegalovirus infection and renal transplantation.
    Metselaar HJ; Weimar W
    J Antimicrob Chemother; 1989 Jun; 23 Suppl E():37-47. PubMed ID: 2550411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preemptive therapy for the prevention of cytomegalovirus disease in renal transplant recipients: our preliminary experience.
    Paudice N; Mehmetaj A; Zanazzi M; Moscarelli L; Piperno R; Di Maria L; Bertoni E; Salvadori M
    Transplant Proc; 2009 May; 41(4):1204-6. PubMed ID: 19460517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts.
    Balfour HH; Chace BA; Stapleton JT; Simmons RL; Fryd DS
    N Engl J Med; 1989 May; 320(21):1381-7. PubMed ID: 2541335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytomegalovirus prophylaxis in pediatric kidney transplantation: the Dutch experience.
    Jongsma H; Bouts AH; Cornelissen EA; Beersma MF; Cransberg K
    Pediatr Transplant; 2013 Sep; 17(6):510-7. PubMed ID: 23890076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis.
    Opelz G; Daniel V; Naujokat C; Fickenscher H; Döhler B
    Lancet Oncol; 2007 Mar; 8(3):212-8. PubMed ID: 17329191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
    Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
    Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial.
    Singh N; Yu VL; Mieles L; Wagener MM; Miner RC; Gayowski T
    Ann Intern Med; 1994 Mar; 120(5):375-81. PubMed ID: 8304654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prophylaxis against herpes infections in kidney transplant patients with special emphasis on CMV.
    Birkeland SA; Andersen HK; Gahrn-Hansen B
    Scand J Infect Dis; 1998; 30(3):221-6. PubMed ID: 9790127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.